Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies

Robert Zivadinov,Alexander J. Keenan,Hoa H. Le,Maria Ait-Tihyaty,Kavita Gandhi,Matthew L. Zierhut,Elizabeth M. Salvo-Halloran,Abril Oliva Ramirez,Vivian Vuong,Sumeet Singh,Brian Hutton
DOI: https://doi.org/10.1186/s12883-024-03888-6
2024-10-10
BMC Neurology
Abstract:Brain volume loss (BVL) has been identified as a predictor of disability progression in relapsing multiple sclerosis (RMS). As many available disease-modifying treatments (DMTs) have shown an effect on slowing BVL, this is becoming an emerging clinical endpoint in RMS clinical trials.
clinical neurology
What problem does this paper attempt to address?